Developing and Manufacturing mRNA Vaccines at Scale – Lessons Gained from the COVID-19 Pandemic
Andreas N. Kuhn, PhDAndreas N. Kuhn, PhD, Senior Vice President and Head, RNA Biochemistry and Manufacturing, BioNTech AG
Andreas Kuhn, Ph.D., has worked in the field of RNA biochemistry and molecular biology for more than twenty-five years. His work on mRNA-based therapeutics began in 2007, and Andreas joined BioNTech RNA Pharmaceuticals GmbH shortly after its founding. His main focus in his current role as Senior Vice President RNA Biochemistry & Manufacturing is expanding proprietary technologies to increase the efficacy of mRNA therapeutics and to optimize GMP-compatible manufacturing processes for RNA. He has co-authored several publications and patents ranging from basic research on RNA to its application as a diagnostic and therapeutic agent.

Major CMC Challenges when Developing a COVID-19 Vaccine
Ingrid KR KromannIngrid KR Kromann, Head, CMC, Coalition for Epidemic Preparedness Innovations (CEPI)
Ingrid Kromann started 01 March 2020 as Head of CMC, CEPI, UK. The CEPI CMC team is facilitating the vaccine developers in process development and scale up activities. Ingrid has a background as chemical engineer. She has more than 25 years’ experience of working with vaccines through her employment at Statens Serum Institut, Denmark. For the last 16 years, Ingrid led the Vaccine development department at Statens Serum Institut, and has developed more than 10 different vaccines from research to clinical trials, mostly within Tuberculosis, Polio and Chlamydia.

Speaker Proposal